What Is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer

[1]  H. Putter,et al.  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.

[2]  D. Miller,et al.  Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 2012 .

[3]  A. Ashworth,et al.  Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.

[4]  M. Hatae,et al.  Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[6]  G. Thomas.  A Role for Adjuvant Radiation in Clinically Early Carcinoma of the Endometrium? , 2010, International Journal of Gynecologic Cancer.

[7]  C. Creutzberg.  Adjuvant Chemotherapy for Endometrial Cancer: Unproven , 2010, International Journal of Gynecologic Cancer.

[8]  M. Kaneuchi,et al.  Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis , 2010, The Lancet.

[9]  L. Ramondetta,et al.  Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. , 2009, Gynecologic oncology.

[10]  L. Akslen,et al.  Biologic markers in endometrial cancer treatment , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[11]  Hein Putter,et al.  Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Neven,et al.  Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma , 2009, International Journal of Gynecologic Cancer.

[13]  S. Pecorelli.  Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[14]  T. Whelan,et al.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.

[15]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[16]  R. Wenham,et al.  The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[17]  G. Fleming,et al.  Current treatment of metastatic endometrial cancer. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[18]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[19]  T. Luukkaala,et al.  Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. , 2008, Gynecologic oncology.

[20]  H. Andersson,et al.  Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long‐ term follow‐ up , 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[21]  Andrea Mariani,et al.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. , 2008, Gynecologic oncology.

[22]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[23]  H. Kölbl,et al.  Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). , 2007, Gynecologic oncology.

[24]  I. Simera,et al.  Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. Fleming,et al.  The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[26]  D. Smith,et al.  Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis , 2007, International Journal of Gynecologic Cancer.

[27]  S. Pignata,et al.  A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group , 2007, British Journal of Cancer.

[28]  Y. Taketani,et al.  Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma. , 2007, Gynecologic oncology.

[29]  J F Tierney,et al.  Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Chan,et al.  Therapeutic role of lymph node resection in endometrioid corpus cancer , 2006, Cancer.

[31]  J. Cooper,et al.  Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. , 2006, Gynecologic oncology.

[32]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[33]  R. Barakat,et al.  Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study , 2006, International Journal of Gynecologic Cancer.

[34]  T. Lesnick,et al.  Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. , 2006, Gynecologic oncology.

[35]  J. Thigpen,et al.  Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Koper,et al.  Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. , 2005, International journal of radiation oncology, biology, physics.

[37]  J. Sorosky,et al.  Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study , 2005 .

[38]  C. Michener,et al.  Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[39]  A. Berchuck,et al.  Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Fanning,et al.  Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. , 2005, American journal of obstetrics and gynecology.

[41]  D. Alberts,et al.  Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. , 2005, Gynecologic oncology.

[42]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[45]  C. L. Creutzberg.  Response to the letter to the editor by Pijnenborg et al. , 2004 .

[46]  P. Maisonneuve,et al.  Carcinoma of the corpus uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[47]  M. Piccart,et al.  Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  P. Maisonneuve,et al.  Carcinoma of the Corpus Uteri , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[49]  K. Swenerton,et al.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Mundt,et al.  Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[51]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[52]  R. Kurman,et al.  Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. , 1990, Gynecologic oncology.

[53]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[54]  J. V. Bokhman.  Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.

[55]  V. Abeler,et al.  Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.